These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30543020)

  • 1. Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional Analysis.
    Wallach JD; Egilman AC; Ross JS; Woloshin S; Schwartz LM
    J Gen Intern Med; 2019 Apr; 34(4):492-495. PubMed ID: 30543020
    [No Abstract]   [Full Text] [Related]  

  • 2. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.
    Skydel JJ; Luxkaranayagam AT; Dhruva SS; Ross JS; Wallach JD
    JAMA Netw Open; 2019 May; 2(5):e193410. PubMed ID: 31074812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
    Wallach JD; Ross JS; Naci H
    Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.
    Wallach JD; Egilman AC; Dhruva SS; McCarthy ME; Miller JE; Woloshin S; Schwartz LM; Ross JS
    BMJ; 2018 May; 361():k2031. PubMed ID: 29794072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety in numbers--monitoring risk in approved drugs.
    Okie S
    N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
    [No Abstract]   [Full Text] [Related]  

  • 7. US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018.
    Skydel JJ; Zhang AD; Dhruva SS; Ross JS; Wallach JD
    Clin Trials; 2021 Aug; 18(4):488-499. PubMed ID: 33863236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How pharmaceuticals are developed.
    Vander Elst E
    J Am Dent Assoc; 1994 Jan; 125 Suppl():40S-44S. PubMed ID: 8294674
    [No Abstract]   [Full Text] [Related]  

  • 9. Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015.
    MacGregor A; Zhang AD; Wallach JD; Ross JS; Herder M
    JAMA Netw Open; 2020 Jul; 3(7):e209498. PubMed ID: 32706379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Publication and Reporting of the Results of Postmarket Studies for Drugs Required by the US Food and Drug Administration, 2009 to 2013.
    Cruz ML; Xu J; Kashoki M; Lurie P
    JAMA Intern Med; 2017 Aug; 177(8):1207-1210. PubMed ID: 28505214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of clinical trial settings of drugs commonly used in primary care and approved between 2005 and 2012.
    Crossley JR; Tan TP; Smith KH; Ross JS; Merenstein DJ
    J Gen Intern Med; 2018 Sep; 33(9):1431-1432. PubMed ID: 29777429
    [No Abstract]   [Full Text] [Related]  

  • 12. Withdrawing FDA approval of midodrine after marketing.
    Holtzman NA; Starfield B
    JAMA; 2011 Feb; 305(8):781-2; author reply 782. PubMed ID: 21343575
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018.
    Wallach JD; Ramachandran R; Bruckner T; Ross JS
    JAMA Netw Open; 2021 Nov; 4(11):e2133601. PubMed ID: 34751764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulators scramble to tighten loopholes after heparin debacle.
    Jia H
    Nat Biotechnol; 2008 May; 26(5):477-8. PubMed ID: 18464756
    [No Abstract]   [Full Text] [Related]  

  • 15. A drug is not a drug is not a drug: a commentary.
    Struijker Boudier HA
    Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):437-8. PubMed ID: 12426926
    [No Abstract]   [Full Text] [Related]  

  • 16. How the US drug safety system should be changed.
    Strom BL
    JAMA; 2006 May; 295(17):2072-5. PubMed ID: 16670415
    [No Abstract]   [Full Text] [Related]  

  • 17. Postmarket Clinical Evidence for High-Risk Therapeutic Medical Devices Receiving Food and Drug Administration Premarket Approval in 2010 and 2011.
    Rathi VK; Krumholz HM; Masoudi FA; Ross JS
    JAMA Netw Open; 2020 Aug; 3(8):e2014496. PubMed ID: 32857145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IOM advises FDA on ethics in postmarket safety trials.
    Kuehn BM
    JAMA; 2010 Aug; 304(6):627. PubMed ID: 20699450
    [No Abstract]   [Full Text] [Related]  

  • 19. The report by the Institute of Medicine and postmarketing surveillance.
    Klein DF
    Arch Gen Psychiatry; 1999 Apr; 56(4):353-4. PubMed ID: 10197831
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug safety on trial. Last year's withdrawal of the anti-arthritis drug Vioxx triggered a debate about how to better monitor drug safety even after approval.
    Greener M
    EMBO Rep; 2005 Mar; 6(3):202-4. PubMed ID: 15741969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.